Abstract:Abstract Concern regarding the human health implications that exposure to nano- and microplastic particles (NMPs) potentially represents is increasing. While there have been several years of research reporting on the ecotoxicological effects of NMPs, human health toxicology studies have only recently emerged. The available human health hazard data are thus limited, with potential concern regarding the relevance and reliability for understanding the potential human health implications. In this study we develop and apply a NMP toxicity screening assessment tool (NMP-TSAT) for evaluating human health effects studies against a suite of quality assurance and quality control (QA/QC) criteria for both in vivo and in vitro studies. A total of 74 studies representing either inhalation or oral exposure pathways were identified and evaluated. Assessment categories include particle characterization, experimental design, and applicability for risk assessment; with critical and non-critical criteria organized to allow screening and prioritization. It is observed that the majority of studies evaluated using the NMP-TSAT have been performed on monodisperse particles, predominately spheres (≈60%), consisting of polystyrene (≈46%). The majority of studies have tested particles < 5 μm, with a minimal particle size of 10 nm and a maximum particle size of about 200 μm. The total assessment score (TAS) possible for in vivo studies is 52, whereas for in vitro studies it is 46, which is based on receiving a maximum score of 2 against 26 and 23 criteria, respectively. The evaluated TAS ranged from between 12 and 44 and 16–34, for in vivo and in vitro studies, respectively. Given the challenges associated with prioritizing studies based on ranking them according to their TAS we propose a Tiered approach, whereby studies are initially screened based on how they score against various critical criteria, which have been defined for their relevance for assessing the hazards and risks for human health. In this instance, studies that score a minimum of ‘1’ against each of the critical criteria, regardless of how they rank according to their TAS, are prioritized as part of a Tier 1 screening and prioritization phase, which would then be followed by an expert evaluation, representing a Tier 2 level of assessment. Using this approach we identify 10 oral ingestion and 2 inhalation studies that score at least 1 against all critical criteria. Lastly, several key observations for strengthening future effects studies are identified, these include a need for the generation and access to standard reference materials representative of human exposure to NMPs for use in toxicity test systems and/or the improved characterization and verification of test particle characteristics, and the adoption of study design guidance, such as recommended by OECD, when conducting either in vivo inhalation or oral ingestion toxicity tests.

Opportunities and Challenges Related to Saturation of Toxicokinetic Processes: Implications for Risk Assessment

Incorporating Human Exposure Information in a Weight of Evidence Approach to Inform Design of Repeated Dose Animal Studies.

Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics

Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing

Human biomonitoring and toxicokinetics as key building blocks for next generation risk assessment

Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing

Exploring Greater Flexibility for Chronic Toxicity Study Designs to Support Human Safety Assessment While Balancing 3Rs Considerations

Advancing environmental toxicology through chemical dosimetry: external exposures versus tissue residues

Environmental Risk Assessment of Time-Variable Toxicant Exposure with Toxicokinetic-Toxicodynamic Modeling of Sublethal Endpoints and Moving Time Windows: A Case Study with Ceriodaphnia dubia

Incorporating new approach methods (NAMs) data in dose-response assessments: The future is now!

From vision toward best practices: Evaluating in vitro transcriptomic points of departure for application in risk assessment using a uniform workflow

Recommended approaches to the scientific evaluation of ecotoxicological hazards and risks of endocrine-active substances

Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities

Balancing Blood Sample Volume with 3rs: Implementation and Best Practices for Small Molecule Toxicokinetic Assessments in Rats

A Systemic Exposure-Based Alternative to the Maximum Tolerated Dose for Carcinogenicity Studies of Human Therapeutics

New approach methodologies in human regulatory toxicology - Not if, but how and when!

Review of dose setting for the extended one-generation reproductive toxicity studies (OECD TG 443): Considerations on ECHA's dose level selection recommendations

An automated computational data pipeline to rapidly acquire, score, and rank toxicological data for ecological hazard assessment

Screening and prioritization of nano- and microplastic particle toxicity studies for evaluating human health risks – development and application of a toxicity study assessment tool

Enabling Transparent Toxicokinetic Modeling for Public Health Risk Assessment

Considerations for the development of guidance on dose level selection for developmental and reproductive toxicity studies